Phase 3 Type 2 Diabetes Trial, Not Yet Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People who have been diagnosed with Type 2 Diabetes for at least 12 weeks, and who have been on a stable dose of metformin (either alone or combined with a type of diabetes medication called an SGLT2 inhibitor) for at least 12 weeks before the screening visit.
- People whose blood sugar control measure (called HbA1c, a 3-month average blood sugar test) falls within a specific range — at least 7.5% but no more than 11.0% at the first screening visit, and at least 7.0% but no more than 11.0% at a later check before joining the trial.
- People with a Body Mass Index (BMI) of 22.5 or higher (BMI is a number calculated from height and weight).
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who have a type of diabetes other than Type 2 Diabetes.
- People who experienced a serious diabetes-related emergency (such as diabetic ketoacidosis, lactic acidosis, or a severe high-blood-sugar crisis) within the 24 weeks before signing the consent form.
- People who have had a severe low blood sugar episode, or repeated low blood sugar episodes without warning symptoms, within the 24 weeks before signing the consent form.
- People with a personal or family history of a specific type of thyroid cancer (medullary thyroid carcinoma), abnormal thyroid cell growth, or a hereditary condition called multiple endocrine neoplasia type 2.
- People with a history of pancreas inflammation (pancreatitis), either sudden or long-term; those with known risk factors for pancreatitis; or those who had gallbladder problems requiring treatment within the 24 weeks before signing the consent form.
- People who have a condition affecting how their stomach empties or how their gut absorbs food — such as having had weight-loss surgery or stomach surgery, irritable bowel syndrome, persistent indigestion, or a condition called gastroparesis (slow stomach emptying).
- People who have used diabetes medications other than metformin or an SGLT2 inhibitor in the 12 weeks before signing the consent form (a short course of insulin lasting 7 days or fewer for illness, stress, or surgery is an exception).
- People whose blood haemoglobin level (a measure of red blood cell health) is below 100 g/L (for women) or below 110 g/L (for men).
- People whose fasting blood sugar level is 13.9 mmol/L or higher.
- People with liver enzyme levels (AST or ALT) more than three times the upper limit of the normal range.
- People with a total bilirubin level (a liver-related measure) more than one and a half times the upper limit of the normal range.
- People with fasting triglyceride levels (a type of fat in the blood) above 5.6 mmol/L (500 mg/dL).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Linong Ji, Peking University People's Hospital
Phone: +86 19157709998
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change from baseline in Hemoglobin A1c (HbA1c)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.